Successful Development And Manufacturing Of Vaccines Containing Aluminum Adjuvants

By Jackie Fan, MSc (ENG), PEng, Manager, Manufacturing Science & Technology Department

Aluminum adjuvants, including aluminum phosphate, aluminum hydroxide, aluminum potassium sulfate, and amorphous aluminum hydroxyphosphate sulfate—collectively known as aluminum salts or alum—are increasingly utilized in next-generation vaccines due to their effectiveness in enhancing vaccine potency. These adjuvants work by improving the immunogenicity of vaccine antigens, leading to a stronger overall immune response. Research has shown that vaccines formulated with aluminum salts can achieve significant efficacy with less frequent administration, making them a valuable component in modern vaccine development.

Collaborating with a CDMO experienced in the development and manufacturing of next-generation vaccines is crucial for navigating the complexities of incorporating aluminum adjuvants. Such partnerships can streamline the manufacturing process, ensuring that the integration of these adjuvants enhances vaccine efficacy while maintaining compliance with regulatory standards. By leveraging the expertise of a skilled CDMO, developers can optimize formulations, reduce production timelines, and ultimately improve the success rate of their vaccine products.